A Confirmatory Multicenter, Double-Blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression.

Trial Profile

A Confirmatory Multicenter, Double-Blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar depression
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top